{"url":"https://newsforagent.com/news/2026-11-21/neuropace-sbs-securities-investigation","markdown_url":"https://newsforagent.com/news/2026-11-21/neuropace-sbs-securities-investigation.md","title":"NeuroPace Faces SBS Securities Investigation","headline":"Schall, Brown & Schwartz Investigates NeuroPace Over Q3 2026 Revenue Decline and Guidance Cut","description":"Schall, Brown & Schwartz is investigating NeuroPace for possible securities law violations after Q3 2026 revenue fell year over year and shares dropped 37.1%.","section":"Legal & Disputes","published_at":"2026-11-21T21:26:06+00:00","modified_at":"2026-11-21T21:26:06+00:00","author":"News Desk","key_takeaways":["Schall, Brown & Schwartz LLP is investigating NeuroPace for possible securities law violations tied to its Q3 2026 results.","NeuroPace reported a year-over-year revenue decline and cut its full-year 2026 revenue guidance on November 13, 2026.","NeuroPace shares fell 37.1% on the day the Q3 2026 results were released."],"companies":[{"name":"NeuroPace","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000dnw/neuropace","website":"http://www.neuropace.com"}],"source":{"publisher":"Business Wire","title":"NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with SBS Law","url":"https://www.businesswire.com/news/home/20261121941303/en/"},"other_sources":[{"publisher":"The future of trading","url":"https://capital.com/en-int/news/amd-investors-have-opportunity-to-join-advanced-micro-devices-inc"}],"tags":["Legal & Disputes","NeuroPace"],"body_markdown":"Schall, Brown & Schwartz LLP is investigating [NeuroPace](https://akta.pro/company-profiles/0000dnw/neuropace), Inc. for possible violations of the securities laws, the firm said in a [Business Wire](https://www.businesswire.com/news/home/20261121941303/en/) announcement on November 21, 2026. The investigation concerns whether NeuroPace issued false or misleading statements or failed to disclose information pertinent to investors.\n\n## What the SBS Investigation Alleges\n\nThe investigation centers on NeuroPace's Q3 2026 financial results, which the company reported on November 13, 2026. NeuroPace disclosed a year-over-year decline in revenues and cut its full-year 2026 revenue guidance, attributing the shortfall in part to \"local operational issues.\" Shares of NeuroPace fell 37.1% on the same day. SBS, a national shareholder rights litigation firm, invited shareholders who suffered a loss to contact Brian Schall or David Schwartz to discuss their rights free of charge. The firm's announcement follows a similar [investigation into Advanced Micro Devices](https://capital.com/en-int/news/amd-investors-have-opportunity-to-join-advanced-micro-devices-inc) that SBS announced on November 20, 2026, citing a Hunterbrook report alleging AMD issued false statements and bills over 20% of revenue to China and Hong Kong; AMD shares fell more than 7.7% that day.\n\n## NeuroPace's Core RNS Business\n\nNeuroPace markets the FDA-approved RNS System, a closed-loop brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy, according to akta.pro [company records](https://akta.pro/company-data). The Mountain View company was founded in 1997 and serves Level 4 epilepsy centers in the U.S. The same records show NeuroPace raised its full-year 2026 revenue guidance to $99-101 million on a continuing-operations basis, reflecting expected 21-23% underlying growth in its core RNS System business. NeuroPace reported full-year 2025 revenue of $100 million, representing 25% growth compared to 2024.\n\n## NeuroPace's Guidance History Before the Cut\n\nNeuroPace's guidance trajectory shifted during 2026. In August 2026, the company reported second-quarter earnings with a narrowed net loss of US$6.20 million and revenue growth of 17% to US$22.8 million, while revising its full-year 2026 revenue guidance upward to between $99.5 million and $101.5 million, according to Simply Wall St. ScanX reported the same month that the raised range exceeded the consensus estimate of $99.913 million. In September 2026, Investing.com reported that NeuroPace's IGE indication faced an open FDA review after a non-approvable letter, and that the NAUTILUS trial missed its primary endpoint but showed 100% median seizure reduction at 24 months.\n\n## NeuroPace's Next Steps\n\nNeuroPace has not stated a date for the conclusion of the SBS investigation. The company's IGE indication remains under FDA review following the non-approvable letter, according to Investing.com.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}